Ｌａｆｕｔｉｄｉｎｅの透析患者における体内動態の検討

• 古橋 三義

  新風会丸山病院

• 中島 光好

  浜松シーピーティー研究所

書誌事項

タイトル別名

• Pharmacokinetic study of lafutidine in patients under hemodialysis.

抄録

H₂-receptor antagonist is an effective drug for peptic ulcers in hemodialysis patients. It was reported that the urinary excretion rate of lafutidine, a new H₂-receptor antagonist was lower than those of other H₂-receptor antagonists, and the plasma concentration profiles of lafutidine in elderly subjects with renal dysfunction [Ccr: 20-60 (average: 45.2) mL/min] were similar to those in elderly subjects with normal renal function (Ccr: ≥61mL/min) and healthy subjects. In the present study, we evaluated pharmacokinetics of lafutidine in hemodialysis patients. A lafutidine tablet (10mg) was given to 6 patients during the inter- and intra-dialysis period. The age of these patients was between 49 and 72 years, and the duration of dialysis was between 11 months and 14 years. Plasma concentration of lafutidine were determined to obtain pharmacokinetic parameters. In addition, the extraction rate of lafutidine by hemodialysis was measured. When lafutidine was orally administered without hemodialysis, Tmax of 0.8±0.1hr, Cmax of 336±40ng/mL, t_1/2 of 6.71±0.30hr, and AUC_(0-24hr) of 2278±306ng·hr/mL were obtained. After hemodialysis, Tmax of 2.6±0.5hr, Cmax of 226±36ng/mL, t_1/2 was 4.57±0.24hr, and AUC_(0-6hr) of 853±128ng·hr/mL were obtained. In addition, lafutidine was extracted by all hemodialysis membranes used in this study with a 7 to 18% extraction rate. t_1/2 of lafutidine was not prolonged even in patients with loss of renal function. Prolonged t_1/2 (6.7hr) was less than the administration period (every 12hr) indicating that the administration pattern of lafutidine need not change for hemodialysis patients. However, Cmax was approximately doubled in hemodialysis patients administered oral lafutidine compared to that in healthy subjects. Therefore, it might be preferable to initiate administration of lafutidine at a lower dose.

収録刊行物

• 日本透析医学会雑誌

  日本透析医学会雑誌 35 (1), 35-42, 2002

  一般社団法人 日本透析医学会

キーワード

• H₂受容体拮抗剤
• 体内動態
• 血液透析

詳細情報

• CRID: 1390001204675913216
• NII論文ID: 130003721633
• NII論文ID: 10008362074
• NII書誌ID: AN10432053
• DOI: 10.4009/jsdt.35.35
• ISSN: 1883082X
• ISSN: 13403451
• Web Site: https://search.jamas.or.jp/link/ui/2002125195
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可